Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
On the 3rd and 4th of July, the cosmopolitan city of Milan, Italy, played host to the bi-annual project meeting of VANGUARD. The meeting was
Team members of the VANGUARD project travelled to Igls in Austria for the annual consortium meeting which was held on 22 January 2023. The full
During the annual VANGUARD project meeting 2022 held in Geneva, Switzerland we spoke to all project partners involved about the objectives of VANGUARD, their role
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874700